ArticleJournal of nanobiotechnology2026
ROS-responsive EGCG-Fe-Cur nanosystems for radioprotection through antioxidant and inhibition of ferroptosis pathways.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Acute radiation sickness (ARS) is a systemic disease caused by exposure to high doses of ionizing radiation within a short period. The development of effective high-dose radiation protectants remains a critical yet unresolved challenge in this field. The fabrication of metal-phenolic networks (MPNs) is emerging as a promising strategy for the prevention and treatment of ARS. In light of this, we have adopted a novel nano-self-assembly strategy based on metal-organic coordination synthesis to develop the EGCG-Fe-Cur nanosystem, which not only exhibits robust in vitro antioxidant activity and reactive oxygen species (ROS) responsiveness but also enhances bioavailability and water solubility, thereby minimizing adverse effects. In vitro cell studies have shown that EGCG-Fe-Cur alleviates G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.